The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear. METHODS: (stage 1 or 2 CKD). Patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary outcome, assessed in a time-to-event analysis, was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The first secondary outcome was a composite of kidney failure, a sustained decrease from baseline of at least 40% in the eGFR, or death from renal causes. Safety was assessed as investigator-reported adverse events. RESULTS: A total of 7437 patients underwent randomization. Among the patients included in the analysis, during a median follow-up of 3.4 years, a primary outcome event occurred in 458 of 3686 patients (12.4%) in the finerenone group and in 519 of 3666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P = 0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90). The secondary composite outcome occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 1.01). The overall frequency of adverse events did not differ substantially between groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%). CONCLUSIONS: Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in kidney failure: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) outcome trial (460) demonstrates a significant relationship between reduction in moderately increased albuminuria and reduction in cardiovascular risk.”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [460]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Discontinuation of trial regimen was higher among those on fi nerenone than placebo (1.2% vs. 0.4%).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with T2D and albuminuria are known to be at high risk of CKD progression and cardiovascular events, and the FIDELIO-DKD and FIGARO-DKD trials demonstrated that fi nerenone reduced these events (particularly CKD progression and heart failure) among such patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pooled analysis of two complementary trials comprising 13 026 patients with a broad spectrum of CKD and type 2 diabetes, all treated with an optimized dose of an ACEi or ARB,7 , 10 provides robust evidence of both cardiovascular and kidney protection with finerenone vs. placebo.”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People with type 2 diabetes and CKD should be considered for treatment with finerenone to reduce cardiovascular outcomes and the risk of CKD progression (239–242).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finerenone was investigated in two complementary phase 3 studies of patients with T2D, kidney disease (defined primarily as ACR ≥30 mg/g), and potassium <4.8 mmol/L and is the only ns-MRA approved in the world for slowing CKD progression and reducing cardiovascular events.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in ESKD: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“There was a 13% lower risk of the primary cardiovascular composite outcome, which included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“The secondary composite kidney outcome, which included kidney failure, sustained decrease from baseline of at least 40% in eGFR, or death from kidney causes, was not signi fi cantly different between fi nerenone and placebo (HR 0.87, 95% CI 0.76 -1.01).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“On average, there was only a small reduction in systolic blood pressure (3 mm Hg) with fi nerenone compared to placebo, and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“and fi nerenone reduced the risk of kidney and cardiovascular outcomes in 2 pivotal outcome trials.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the primary cardiovascular composite outcome risk in a broader patient population than studied in FIDELIO-DKD (patients with stage 2–4 CKD and moderately increased albuminuria, or stage 1–2 CKD with severely increased albuminuria).7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The FIDELIO-DKD trial was designed to detect a treatment effect of finerenone on kidney failure endpoints, whereas the FIGARO-DKD trial aimed to detect an effect on a cardiovascular composite primary endpoint.7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76-0.98];P = 0.03) in people with type 2 diabetes and CKD (248).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56-0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56–0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76–0.98]; P = 0.03) in people with type 2 diabetes and CKD (240).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In summary, FIDELIO-DKD and FIGARO-DKD demonstrated cardiovascular and kidney benefits for finerenone among people with T2D who were treated with standard of care (including an RAS inhibitor at maximally tolerated doses and good control of glycemia and BP) who were at high residual risk, based largely on albuminuria (ACR ≥30 mg/g).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Physical activity and aerobic exercise guidelines are similar in persons with T2D independent of lean vs overweight/obese BMI.431,674,727,728”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [431]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, the updated evidence review identifi ed 27 RCTs on MRA, with 5 RCTs comparing nonsteroidal MRA to placebo and/or standard of care.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredIn the citing paper
“According to two large randomized placebo-controlled trials targeted at T2DM and CKD patients, finerenone has been demonstrated to significantly reduce the occurrences of composite renal outcome”
In the citing paper
“and composite cardiovascular outcome (defined as a composite of nonfatal MI, nonfatal stroke, death from cardiovascular causes, or hospitalization for heart failure [HHF]), regardless of patients with or without established cardiovascular disease [16, 17].”
In the citing paper
“Even more recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone has been shown to confer both cardiovascular and kidney protection in patients with T2D and CKD, in both a dedicated kidney outcome trial and a dedicated cardiovascular outcome trial [22,23].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [23]
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the composite cardiovascular outcome, which was the primary outcome of the trial (HR: 0.87, 95% CI: 0.76-0.98).26”
In the citing paper
“FIDELIO-DKD and FIGARO-DKD each enrolled people with T2D treated with the maximum-tolerated dose of RASi who had residual albuminuria (ACR $30 mg/g [$3 mg/mmol]) and a nonelevated serum potassium (<4.8 mEq/l at screening).”
In the citing paper
“This recommendation is based on the high-quality evidence from FIDELIO-DKD and FIGARO-DKD (Grade A, summarized above) that finerenone slows progression of CKD and reduces risks of cardiovascular events in this population.25,26”
In the citing paper
“Two large clinical trials (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease [FIDELIO-DKD] 25 and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease [FIGARO-DKD] 26 ) and a pre-specified individual-level combined analysis of these 2 trials (The FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD”
In the citing paper
“To mitigate hyperkalemia risk, the FIDELIO-DKD and FIGARO-DKD trials restricted eligibility to patients with non-elevated serum potassium concentration (after maximizing RASi) and implemented a standardized potassiummonitoring protocol.”
In the citing paper
“The HR of the primary outcome of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization from heart failure was reduced by 13% in patients treated with fi nerenone.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationChronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationCoresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Finerenone in Type 1 Diabetes and Chronic Kidney Disease
Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Groop, P., Ji, L., Jongs, N., Mathieu, C., Pratley, R. E., Rosas, S. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512854 · Cited by 46
Self-citationConsensus statement on the current pharmacological prevention and management of heart failure
Sindone, A. P., Pasquale, C. G. D., Amerena, J. V., Burdeniuk, C., Chan, A., Coats, A. J. S., Hare, D. L., Macdonald, P. S., Sverdlov, A. L., & Atherton, J. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51656 · Cited by 45
Rossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Fonseca, V. A., Umpierrez, G. E., Caramori, M. L., Joseph, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14883 · Cited by 44
Self-citationFilippatos, G. S., Anker, S. D., August, P., Coats, A. J. S., Januzzi, J. L., Mankovsky, B., Rossing, P. R., Ruilope, L. M., Pitt, B., Sarafidis, P. A., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad001 · Cited by 44
Self-citationEbert, T., Anker, S. D., Ruilope, L. M., Fioretto, P., Fonseca, V. A., Umpierrez, G. E., Birkenfeld, A. L., Lawatscheck, R., Scott, C. A. B., Rohwedder, K., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1420 · Cited by 45
Self-citationIntegrating liver endpoints in clinical trials of cardiovascular and kidney disease
Zannad, F. M., Sanyal, A. J., Butler, J., Miller, V., & Harrison, S. A. (2024) · Nature Medicine · doi:10.1038/s41591-024-03223-z · Cited by 46
Zhai, S., Ma, B., Chen, W., & Zhao, Q. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1476029 · Cited by 47
Finerenone in Persons with Chronic Kidney Disease without Diabetes
Heerspink, H. J. L., Neuen, B. L., Agarwal, R., Cherney, D. Z. I., Lam, C. S. P., Tuttle, K. R., Wanner, C., Sarafidis, P. A., Jongs, N., Smeijer, J. D., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604625 · Cited by 44
Self-citationJerome, J. R., Deliyanti, D., Suphapimol, V., Kolkhof, P., & Wilkinson‐Berka, J. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032334 · Cited by 43
Self-citationInfluence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
Luo, X., Xu, J., Zhou, S., Xue, C., Chen, Z., & Mao, Z. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000205 · Cited by 43
Slowing the Progression of Diabetic Kidney Disease
Blazek, O., & Bakris, G. L. (2023) · Cells · doi:10.3390/cells12151975 · Cited by 43
Self-citationMcCullough, P. A., Amin, A., Pantalone, K. M., & Ronco, C. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024139 · Cited by 44
Whitlock, R. H., Leon, S. J., Manacsa, H., Askin, N., Rigatto, C., Fatoba, S., Farag, Y. M. K., & Tangri, N. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad101 · Cited by 43
Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism
Narongkiatikhun, P., Choi, Y. J., Hampson, H. E., Gotzamanis, J., Zhang, G., van Raalte, D. H., de Boer, I. H., Nelson, R. G., Tommerdahl, K. L., McCown, P. J., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.019 · Cited by 42
Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Theodorakopoulou, M. P., Ortíz, A., Fernández‐Fernández, B., Kanbay, M., Minutolo, R., & Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae278 · Cited by 46
Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases
Azizi, M., Mallart-Riancho, J., & Amar, L. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae823 · Cited by 42
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., Muta, Y., Oda, N., Nagata, D., Takahashi, H., & Tanabe, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754239 · Cited by 43
Lerma, E. V., & Wilson, D. J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094770 · Cited by 42
Alicic, R. Z., & Nicholas, S. B. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.05.003 · Cited by 44
Loss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease
Weyrich, M., Cremer, S., Gerster, M., Sarakpi, T., Rasper, T., Zewinger, S., Patyna, S., Leistner, D. M., Heine, G. H., Wanner, C., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069139 · Cited by 41
Joumaa, J. P., Raffoul, A., Sarkis, C., Chatrieh, E., Zaidan, S., Attieh, P., Harb, F., Azar, S. T., & Ghadieh, H. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030727 · Cited by 43
Oka, T., Sakaguchi, Y., Hattori, K., Asahina, Y., Kajimoto, S., Doi, Y., Kaimori, J., & Isaka, Y. (2022) · HYPERTENSION · doi:10.1161/hypertensionaha.121.18360 · Cited by 35
Diabetic kidney disease treatment: new perspectives
Tong, L., & Adler, S. G. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.288 · Cited by 42
Finerenone in diabetic kidney disease: A systematic review and critical appraisal
Singh, A. K., Singh, R., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102638 · Cited by 40
Lerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
Self-citationvon Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 41
Self-citationManagement of traditional risk factors for the development and progression of chronic kidney disease
Lo, R. H., Narasaki, Y., Lei, S., & Rhee, C. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad101 · Cited by 40
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Kreiner, F. F., Schytz, P. A., Heerspink, H. J. L., von Scholten, B. J., & Idorn, T. (2023) · Biomedicines · doi:10.3390/biomedicines11092498 · Cited by 40
The year in cardiovascular medicine 2021: heart failure and cardiomyopathies
Bauersachs, J. K., de Boer, R. A., Lindenfeld, J. M., & Bozkurt, B. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab887 · Cited by 39
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Heinig, R., & Eißing, T. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01312-9 · Cited by 38
Zhang, M., Bao, W., Zheng, Q., Wang, Y., & Sun, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819327 · Cited by 38
Tsukamoto, S., Morita, R., Yamada, T., Urate, S., Azushima, K., Uneda, K., Kobayashi, R., Kanaoka, T., Wakui, H., & Tamura, K. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110161 · Cited by 38
Mende, C. W., Samarakoon, R., & Higgins, P. J. (2023) · American Journal of Nephrology · doi:10.1159/000528783 · Cited by 37
Kelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 37
Updates on New Therapies for Patients with CKD
Tarun, T., Ghanta, S. N., Ong, V., Kore, R. A., Menon, L., Kovesdy, C. P., Mehta, J. L., & Jain, N. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.006 · Cited by 43
Bansal, S., Canziani, M. E. F., Birne, R., Anker, S. D., Bakris, G. L., Filippatos, G. S., Rossing, P. R., Ruilope, L. M., Farjat, A. E., Kolkhof, P., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076444 · Cited by 37
Self-citationJi, C., Zhang, J., Shi, H., Chen, B., Xu, W., Jin, J., & Qian, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02613-2 · Cited by 37
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, J. P., Pitt, B., & Zannad, F. M. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011629 · Cited by 41
Self-citationGaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 40
Pabón, M. A., Filippatos, G. S., Claggett, B. L., Miao, M. Z., Desai, A. S., Jhund, P. S., Henderson, A. D., BRINKER, M. D., Schloemer, P., Hofmeister, L. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.429 · Cited by 38
Self-citationHyperkalemia in Diabetes Mellitus Setting
Goia-Nishide, K., Coregliano-Ring, L., & Rangel, É. B. (2022) · Diseases · doi:10.3390/diseases10020020 · Cited by 39
Novel mechanisms of salt-sensitive hypertension
Vogt, L., Marques, F. Z., Fujita, T., Hoorn, E. J., & Danser, A. H. J. (2023) · Kidney International · doi:10.1016/j.kint.2023.06.035 · Cited by 36
Mineralocorticoid Antagonism in Heart Failure
Chang, J., Ambrosy, A. P., Vardeny, O., Spall, H. G. C. V., Mentz, R. J., & Sauer, A. J. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.007 · Cited by 36
Nuclear receptors in renal health and disease
Luan, Z., Zhang, C., Ming, W., Huang, Y., Guan, Y., & Zhang, X. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103855 · Cited by 38
Cohen, J. B., Bancos, I., Brown, J. M., Sarathy, H., Turcu, A. F., & Cohen, D. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-100438 · Cited by 36
Agarwal, R., Pitt, B., Rossing, P. R., Anker, S. D., Filippatos, G. S., Ruilope, L. M., Kovesdy, C. P., Tuttle, K. R., Vaduganathan, M., Wanner, C., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1505 · Cited by 36
Self-citationMark, P. B., Carrero, J. J., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Coresh, J., Surapaneni, A., Brunskill, N. J., Chalmers, J. P., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac825 · Cited by 35
Jyotsna, F., Mahfooz, K., Patel, T., Parshant, F., Simran, F., Harsha, F., Neha, F., Jyotishna, D., Mishra, D., Subedi, S., et al. (2023) · Cureus · doi:10.7759/cureus.41746 · Cited by 35
Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches
Frățilă, G., Lupusoru, G. E., Sorohan, B. M., Obrișcă, B., Mocanu, V., Lupușoru, M. O. D., & Ismail, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030569 · Cited by 35
Bornstein, S. R., de Zeeuw, D., Heerspink, H. J. L., Schulze, F., Cronin, L., Wenz, A., Tuttle, K. R., Hadjadj, S., & Rossing, P. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15518 · Cited by 35
Self-citationMineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
Matsumoto, S., Henderson, A. D., Shen, L., Yang, M., Swedberg, K. B., Vaduganathan, M., van Veldhuisen, D. J., Solomon, S. D., Pitt, B., Zannad, F. M., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.426 · Cited by 37
Self-citationTu, L., Thuillet, R., Perrot, J., Ottaviani, M., Ponsardin, E., Kolkhof, P., Humbert, M. J. C., Viengchareun, S., Lombès, M., & Guignabert, C. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19207 · Cited by 36
Self-citationMentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 38
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 38
Gourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 34
Sanz‐Gómez, M., Manzano-Lista, F. J., Martín, E. V., González‐Moreno, D., Alcalá, M., Gil‐Ortega, M., Somoza, B., Pizzamiglio, C., Ruilope, L. M., Aránguez, I., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115661 · Cited by 33
Self-citationCellular crosstalk of mesangial cells and tubular epithelial cells in diabetic kidney disease
Jiang, S., & Su, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01323-w · Cited by 33
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
Kobayashi, M., Girerd, N., & Zannad, F. M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae004 · Cited by 33
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 33
Morgen, C. S., Haase, C. L., Oral, T. K., Schnecke, V., Varbo, A., & Borlaug, B. A. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.07.008 · Cited by 32
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 33
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 34
Representation of Low- and Middle-Income Countries in CKD Drug Trials: A Systematic Review
Cojuc‐Konigsberg, G., Güijosa, A., Moscona-Nissan, A., Nordmann-Gomes, A., Canaviri, V. A., Braverman-Poyastro, A., de la Fuente-Ramírez, R., Sánchez, D. N. T., Fuentes-Cepeda, A. D. L., Noyola‐Perez, A., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.06.012 · Cited by 32
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf022 · Cited by 32
Self-citationYang, S., Zhao, L., Mi, Y., & He, W. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14801 · Cited by 32
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
Palanisamy, S., Hernandez, M. F., Chang, T. I., & Mahaffey, K. W. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00269-3 · Cited by 32
Mima, A., Lee, R., Murakami, A., Gotoda, H., Akai, R., KIDOOKA, S., Nakamoto, T., KIDO, S., & Lee, S. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100251 · Cited by 31
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 33
Steroidal MRA Across the Spectrum of Renal Function
Ferreira, J. P., Pitt, B., McMurray, J. J. V., Pocock, S., Solomon, S. D., Pfeffer, M. A., Zannad, F. M., & Rossignol, P. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.06.010 · Cited by 31
Self-citationChen, D., Wu, J., & Li, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055296 · Cited by 31
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 33
Self-citationMoh, M. C., Low, S. K., Shao, Y. M., Subramaniam, T., Sum, C. F., & Lim, S. C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110634 · Cited by 30
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
Piko, N., Bevc, S., Hojs, R., & Ekart, R. (2024) · Pharmaceuticals · doi:10.3390/ph17040418 · Cited by 32
Characterizing the Origins of Primary Aldosteronism
Brown, J. M., Honzel, B., Tsai, L. C., Milks, J., Neibuhr, Y., Newman, A. J., Cherney, M. D., Stouffer, D. G., Auchus, R. J., & Vaidya, A. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.24153 · Cited by 30
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 31
Shokravi, A., Seth, J., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02900-8 · Cited by 32
DeFronzo, R. A., & Bakris, G. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14696 · Cited by 32
Self-citationUchida, H. A., Nakajima, H., Hashimoto, M., Nakamura, A., Nunoue, T., Murakami, K., Hosoya, T., Komoto, K., Taguchi, T., Akasaka, T., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02294-z · Cited by 30
Karakasis, P., Patoulias, D., Popovic, D. S., Pamporis, K., Theofilis, P., Nasoufidou, A., Stachteas, P., Samaras, A., Tzikas, A., Giannakoulas, G. A., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102742 · Cited by 29
Risk-directed management of chronic kidney disease
Blum, M. F., Neuen, B. L., & Grams, M. E. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00931-8 · Cited by 30
Mosaic loss of Y chromosome and mortality after coronary angiography
Weyrich, M., Zewinger, S., Sarakpi, T., Rasper, T., Kleber, M. E., Cremer, S., Zanders, L., Fleck, F., Siegbahn, A. G., Wallentin, L. C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf035 · Cited by 29
Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review
Kim, J. A., Wu, L., Rodriguez, M., Lentine, K. L., Virk, H. U. H., Hachem, K. E., Lerma, E. V., Kiernan, M. S., Rangaswami, J., & Krittanawong, C. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101509 · Cited by 33
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice
Desai, N. R., Navaneethan, S. D., Nicholas, S. B., Pantalone, K. M., Wanner, C., Hamacher, S., Gay, A., & Wheeler, D. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108411 · Cited by 29
Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
Dąbek, B., Dybiec, J., Frąk, W., Fularski, P., Lisińska, W., Radzioch, E., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11102746 · Cited by 36
Mineralocorticoid receptor signalling in primary aldosteronism
Yang, J., Young, M. J., Cole, T. J., & Fuller, P. J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0249 · Cited by 28
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
Shah, M., Awad, A. S., & Abdel‐Rahman, E. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196285 · Cited by 28
Mahmood, A., Dhall, E., Primus, C., Gallagher, A. M., Zakeri, R., Mohammed, S. F., Chahal, C. A. A., Ricci, F., Aung, N., & Khanji, M. Y. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae053 · Cited by 29
Rajagopalan, S., Dobre, M. A., Dazard, J.-E., Vergara-Martel, A., Connelly, K. A., Farkouh, M. E., Gaztañaga, J., Conger, H., Dever, A. M., Razavi-Nematollahi, L., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067620 · Cited by 29
Self-citationFinerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Viswanathan, P., Kolkhof, P., Schloemer, P., Amarante, F., Lam, C. S. P., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00309-7 · Cited by 30
Self-citationWang, C.-A., Lai, H.-W., Chen, J., Wang, W.-J., Lin, L.-C., Chiu, Y., Cheng, C., & Wu, V. (2025) · Nature Communications · doi:10.1038/s41467-025-64640-3 · Cited by 30
Heerspink, H. J. L., Cardona, J., Jolly, S., Pérgola, P. E., Sousa‐Amorim, E. D., Eriksson, A. L., Fredholm, M., Gasparyan, S. B., Guzman, N. J., Hartleib‐Geschwindner, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02014-8 · Cited by 28
Goulooze, S. C., Snelder, N., Seelmann, A., Horvat-Broecker, A., BRINKER, M. D., Joseph, A., Garmann, D., Lippert, J., & Eißing, T. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01083-1 · Cited by 28
Self-citationExpanding the therapy options for diabetic kidney disease
Fioretto, P., & Pontremoli, R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00522-3 · Cited by 28
Mallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 28
Filippatos, G. S., Anker, S. D., Pitt, B., McGuire, D. K., Rossing, P. R., Ruilope, L. M., Butler, J., Jankowska, E. A., Michos, E. D., Farmakis, D. T., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac054 · Cited by 28
Self-citationLima‐Posada, I., Stephan, Y., Soulié, M., Palacios, R., Bonnard, B., Nicol, L., Kolkhof, P., Jaisser, F., & Mulder, P. G. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032536 · Cited by 28
Self-citationTrohman, R. G., Huang, H. D., & Sharma, P. S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1060030 · Cited by 29
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 27
Self-citationAldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Mazzieri, A., Timio, F., Patera, F., Trepiccione, F., Bonomini, M., & Reboldi, G. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000542621 · Cited by 27
Metadata
- Authors
- Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2252-2263
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3194763937
- Cited by
- 1,814
- References
- 32
- Citations by year
- 2026: 439 · 2025: 435 · 2024: 331 · 2023: 315 · 2022: 250 · 2021: 41
- FWCI
- 160.23
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- National University of Singapore (submittedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Bayer (ClinicalTrials.gov NCT02545049)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- mineralocorticoid receptor antagonists, type 2 diabetes, chronic kidney disease, cardiovascular events, heart failure hospitalization, albuminuria, renin-angiotensin system blockade, hyperkalemia, estimated glomerular filtration rate decline, renal failure, cardiorenal outcomes, FIDELIO-DKD
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Proportional Hazards Models, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
